56 related articles for article (PubMed ID: 35241735)
1. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
[TBL] [Abstract][Full Text] [Related]
2. Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells.
Rausch M; Rutz A; Allard PM; Delucinge-Vivier C; Docquier M; Dormond O; Wolfender JL; Nowak-Sliwinska P
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208775
[TBL] [Abstract][Full Text] [Related]
3. Expressions of miR-96-5p, miR-29b-3p, and Their Target Gene THBS1 in Clear Cell Renal Cell Carcinoma and Sunitinib Resistance.
Wu S; Wang Y
Altern Ther Health Med; 2023 Nov; ():. PubMed ID: 37971460
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of serine metabolism enzyme PSAT1 predicts poor prognosis and promotes proliferation, metastasis and drug resistance of clear cell renal cell carcinoma.
Ye J; Huang X; Tian S; Wang J; Wang H; Feng H; Zhao X; Cao S; Xuan Y; Li X; Ma X; Huang Y; Zhang X
Exp Cell Res; 2024 Apr; 437(1):113977. PubMed ID: 38373588
[TBL] [Abstract][Full Text] [Related]
5. Metformin Regulates the miR-205/VEGFA Axis in Renal Cell Carcinoma Cells: Exploring a Clinical Synergism with Tyrosine Kinase Inhibitors.
Krebs M; Kotlyar MJ; Fahl J; Janaki Raman S; Röhrig F; Marquardt A; Kübler H; Kneitz B; Schulze A; Kalogirou C
Urol Int; 2024; 108(1):49-59. PubMed ID: 38035560
[TBL] [Abstract][Full Text] [Related]
6. Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.
Saleeb RM; Farag M; Lichner Z; Brimo F; Bartlett J; Bjarnason G; Finelli A; Rontondo F; Downes MR; Yousef GM
Mol Oncol; 2018 Oct; 12(10):1673-1688. PubMed ID: 29896907
[TBL] [Abstract][Full Text] [Related]
7. ARRDC3 regulates the targeted therapy sensitivity of clear cell renal cell carcinoma by promoting AXL degradation.
Chen M; Yin B; Liu Y; Li M; Shen S; Wu J; Li W; Fan J
Cell Cycle; 2024 Jan; 23(1):56-69. PubMed ID: 38389126
[TBL] [Abstract][Full Text] [Related]
8. Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity
Ghosh S; Garige M; Haggerty PR; Norris A; Chou CK; Wu WW; Shen RF; Sourbier C
Cell Cycle; 2024 Jan; 23(1):43-55. PubMed ID: 38263737
[TBL] [Abstract][Full Text] [Related]
9. Underlying mechanisms of novel cuproptosis-related dihydrolipoamide branched-chain transacylase E2 (DBT) signature in sunitinib-resistant clear-cell renal cell carcinoma.
Lai SW; Weng PW; Yadav VK; Pikatan NW; Yeh CT; Hsieh MS; Chou CL
Aging (Albany NY); 2024 Feb; 16(3):2679-2701. PubMed ID: 38305803
[TBL] [Abstract][Full Text] [Related]
10. IFITM3-mediated activation of TRAF6/MAPK/AP-1 pathways induces acquired TKI resistance in clear cell renal cell carcinoma.
Jeong SU; Park JM; Yoon SY; Hwang HS; Go H; Shin DM; Ju H; Sung CO; Lee JL; Jeong G; Cho YM
Investig Clin Urol; 2024 Jan; 65(1):84-93. PubMed ID: 38197755
[TBL] [Abstract][Full Text] [Related]
11. Integrated genomic and proteomic analyses identify PYGL as a novel experimental therapeutic target for clear cell renal cell carcinoma.
Li M; Zhu G; Liu Y; Li X; Zhou Y; Li C; Wang M; Zhang J; Wang Z; Tan S; Chen W; Zhang H
Heliyon; 2024 Mar; 10(6):e28295. PubMed ID: 38545181
[TBL] [Abstract][Full Text] [Related]
12. Elucidation and Regulation of Tyrosine Kinase Inhibitor Resistance in Renal Cell Carcinoma Cells from the Perspective of Glutamine Metabolism.
Morozumi K; Kawasaki Y; Sato T; Maekawa M; Takasaki S; Shimada S; Sakai T; Yamashita S; Mano N; Ito A
Metabolites; 2024 Mar; 14(3):. PubMed ID: 38535330
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro.
Al-Lamki RS; Hudson NJ; Bradley JR; Warren AY; Eisen T; Welsh SJ; Riddick ACP; O'Mahony FC; Turnbull A; Powles T; Scotrrcc Collaborative ; Reverter A; Harrison DJ; Stewart GD
Biology (Basel); 2020 Apr; 9(4):. PubMed ID: 32272660
[TBL] [Abstract][Full Text] [Related]
14. Integration analysis of PLAUR as a sunitinib resistance and macrophage related biomarker in ccRCC, an in silicon and experimental study.
Yang Q; Ye F; Li L; Chu J; Tian Y; Cao J; Gan S; Jiang A
J Biomol Struct Dyn; 2024 Jan; ():1-18. PubMed ID: 38173169
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance mechanisms in cancers: Execution of pro-survival strategies.
Dhanyamraju PK
J Biomed Res; 2024 Feb; 38(2):95-121. PubMed ID: 38413011
[TBL] [Abstract][Full Text] [Related]
16. miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma.
Park SE; Kim W; Hong JY; Kang D; Park S; Suh J; You D; Park YY; Suh N; Hwang JJ; Kim CS
Sci Rep; 2022 Mar; 12(1):3537. PubMed ID: 35241735
[TBL] [Abstract][Full Text] [Related]
17. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals.
Zhai W; Li S; Zhang J; Chen Y; Ma J; Kong W; Gong D; Zheng J; Xue W; Xu Y
Mol Cancer; 2018 Nov; 17(1):157. PubMed ID: 30419914
[TBL] [Abstract][Full Text] [Related]
19. Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
Xiao W; Lou N; Ruan H; Bao L; Xiong Z; Yuan C; Tong J; Xu G; Zhou Y; Qu Y; Hu W; Gao Y; Ru Z; Liu L; Xiao H; Chen K; Yang H; Zhang X
Cell Physiol Biochem; 2017; 43(6):2420-2433. PubMed ID: 29073615
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
